{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:42:27Z","timestamp":1780692147494,"version":"3.54.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:00:00Z","timestamp":1728950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Secondary hyperparathyroidism is one of the most frequent metabolic abnormalities found in patients with chronic kidney disease. The calcium-sensing receptor senses extracellular calcium and is the principal regulator of parathyroid hormone secretion. Cloning of the calcium-sensing receptor led to the development of calcimimetics, drugs that decrease parathyroid hormone secretion through the positive allosteric modulation of this receptor. Cinacalcet was the first oral calcimimetic approved by the US Food and Drug Administration (FDA) in 2004 for the treatment of secondary hyperparathyroidism in adult patients on dialysis. Although cinacalcet has demonstrated safety and effectiveness, it has two main problems: gastrointestinal side effects that result in poor adherence, and the inhibitory action on CYP2D6 with the possibility of interactions with commonly used medications. To address the problem of oral compliance, Etelcalcetide, a small synthetic polycationic peptide IV calcimimetic was introduced in 2017. This drug showed a 10% greater decrease in serum parathyroid hormone values compared to cinacalcet but no better gastrointestinal tolerance, with greater risk of hypocalcemia. Several structural modifications were introduced in cinacalcet to produce a new compound called evocalcet. This drug, which was introduced in Japan in 2018, has considerably enhanced bioavailability and decreased both the inhibitory effect on CYP2D6 and half of the gastrointestinal side effects of cinacalcet. Finally, a novel non-peptidic injectable calcimimetic agent, upacicalcet, became available in Japan in 2021. This agent has greater clearance by hemodialysis and shows no effect on gastric emptying. More studies are needed comparing the old calcimimetics to the new ones to establish their future role in the treatment of secondary hyperparathyroidism in chronic kidney disease (CKD) G5D.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-024-02119-y","type":"journal-article","created":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:02:02Z","timestamp":1728950522000},"page":"415-421","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["New calcimimetics for secondary hyperparathyroidism in CKD G5D: do they offer advantages?"],"prefix":"10.1093","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1243-6568","authenticated-orcid":false,"given":"Armando L.","family":"Negri","sequence":"first","affiliation":[{"name":"Nephrology Section, Instituto de Investigaciones Metab\u00f3licas, Universidad del Salvador, Libertad 836 1 Floor, Buenos Aires, Argentina 1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Bover","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Germans Trias i Pujol, Badalona, Spain 2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vervloet","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Radboud University Medical Center, Nijmegen, The Netherlands 3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[{"name":"Renal Division, Department of Health Sciences, University of Milan, Milan, Italy 4"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,15]]},"reference":[{"issue":"1","key":"2026012110531349100_CR1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","article-title":"Chronic kidney disease-mineral-bone disorder: a new paradigm","volume":"14","author":"Moe","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026012110531349100_CR2","doi-asserted-by":"crossref","first-page":"913","DOI":"10.2215\/CJN.06040710","article-title":"Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options","volume":"6","author":"Cunningham","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"2026012110531349100_CR3","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012110531349100_CR4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"key":"2026012110531349100_CR5","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transpl"},{"key":"2026012110531349100_CR6","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/MNH.0000000000000326","article-title":"Resurgence of parathyroidectomy: evidence and outcomes","volume":"26","author":"Komaba","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012110531349100_CR7","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/366575a0","article-title":"Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid","volume":"366","author":"Brown","year":"1993","journal-title":"Nature"},{"issue":"2","key":"2026012110531349100_CR8","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1124\/jpet.103.057273","article-title":"Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl","volume":"308","author":"Nemeth","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"2026012110531349100_CR9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2215\/CJN.01760215","article-title":"Clinical and practical use of calcimimetics in dialysis patients with secondary hyperparathyroidism","volume":"11","author":"Bover","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"2026012110531349100_CR10","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"2026012110531349100_CR11","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2026012110531349100_CR12","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/ndt\/gfs356","article-title":"Protocol adherence and the progression of cardiovascular calcification in the ADVANCE study","volume":"28","author":"Ure\u00f1a-Torres","year":"2013","journal-title":"Nephrol Dial Transpl"},{"issue":"26","key":"2026012110531349100_CR13","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis","volume":"367","author":"EVOLVE Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2026012110531349100_CR14","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1210\/jc.2013-2975","article-title":"The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial","volume":"98","author":"Parfrey","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2026012110531349100_CR15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.2215\/CJN.10221014","article-title":"The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial","volume":"10","author":"Floege","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"2026012110531349100_CR16","doi-asserted-by":"crossref","first-page":"G1084","DOI":"10.1152\/ajpgi.00571.2004","article-title":"The calcium-sensing receptor acts as a modulator of gastric acid secretion in freshly isolated human gastric glands","volume":"289","author":"Dufner","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"1","key":"2026012110531349100_CR17","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0245785","article-title":"The effect of evocalcet on vagus nerve activity of the gastrointestinal tract in miniature pigs","volume":"16","author":"Tokunaga","year":"2021","journal-title":"PLoS One"},{"issue":"5","key":"2026012110531349100_CR18","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2165\/00003088-200948050-00002","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride","volume":"48","author":"Padhi","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2026012110531349100_CR19","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1124\/mol.115.098392","article-title":"Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action","volume":"88","author":"Alexander","year":"2015","journal-title":"Mol Pharmacol"},{"issue":"6","key":"2026012110531349100_CR20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/jcph.1090","article-title":"Clinical pharmacokinetics and pharmacodynamics of etelcalcetide, a novel calcimimetic for treatment of secondary hyperparathyroidism in patients with chronic kidney disease on hemodialysis","volume":"58","author":"Wu","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"2026012110531349100_CR21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2016.19456","article-title":"Effect of etelcalcetide vs placebo on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: two randomized clinical trials","volume":"317","author":"Block","year":"2017","journal-title":"JAMA"},{"issue":"7","key":"2026012110531349100_CR22","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3390\/jcm8071066","article-title":"Etelcalcetide in patients on hemodialysis with severe secondary hyperparathyroidism: multicenter study in real life","volume":"8","author":"Russo","year":"2019","journal-title":"J Clin Med"},{"issue":"2","key":"2026012110531349100_CR23","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000496562","article-title":"Improved control of secondary hyperparathyroidism in hemodialysis patients switching from oral cinacalcet to intravenous etelcalcetide, especially in nonadherent patients","volume":"48","author":"Xipell","year":"2019","journal-title":"Blood Purif"},{"issue":"3","key":"2026012110531349100_CR24","first-page":"84","article-title":"Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patient\u2019s adherent and non-adherent to oral calcimimetics","volume":"14","author":"Arenas","year":"2020","journal-title":"Clin Kidney J"},{"issue":"3","key":"2026012110531349100_CR25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/j.ajkd.2021.05.020","article-title":"Etelcalcetide utilization, dosing titration, and chronic kidney disease-mineral and bone disease (CKD-MBD) marker responses in US hemodialysis patients","volume":"79","author":"Karaboyas","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2026012110531349100_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100475","article-title":"Etelcalcetide versus cinacalcet in hemodialysis patients in the United States: a facility calcimimetic approach to assess real-world effectiveness","volume":"4","author":"Karaboyas","year":"2022","journal-title":"Kidney Med"},{"issue":"4","key":"2026012110531349100_CR27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.3390\/healthcare10040709","article-title":"Real-World evaluation of calcimimetics for the treatment of secondary hyperparathyroidism in chronic kidney disease, in an Italian clinical setting","volume":"10","author":"Perrone","year":"2022","journal-title":"Healthcare (Basel)"},{"issue":"11","key":"2026012110531349100_CR28","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1124\/dmd.108.022376","article-title":"The molecular basis of CYP2D6-mediated N-dealkylation: balance between metabolic clearance routes and enzyme inhibition","volume":"36","author":"Bonn","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"2026012110531349100_CR29","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/cr.2016.36","article-title":"Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor","volume":"26","author":"Leach","year":"2016","journal-title":"Cell Res"},{"issue":"11","key":"2026012110531349100_CR30","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.bmcl.2018.04.055","article-title":"Discovery of evocalcet, a next generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism","volume":"28","author":"Miyazaki","year":"2018","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"2026012110531349100_CR31","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.kint.2018.05.013","article-title":"Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism","volume":"94","author":"Fukagawa","year":"2018","journal-title":"Kidney Int"},{"issue":"1","key":"2026012110531349100_CR32","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1038\/s41598-019-42017-z","article-title":"Long-term efficacy and safety of evocalcet in Japanese patients with secondary hyperparathyroidism receiving hemodialysis","volume":"9","author":"Yokoyama","year":"2019","journal-title":"Sci Rep"},{"key":"2026012110531349100_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175936","article-title":"Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor in vitro and in vivo","volume":"956","author":"Goto","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"2026012110531349100_CR34","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2022.116613","article-title":"Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model","volume":"167","author":"Sato","year":"2023","journal-title":"Bone"},{"issue":"10","key":"2026012110531349100_CR35","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2215\/CJN.0000000000000253","article-title":"Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a randomized placebo-controlled trial","volume":"18","author":"Shigematsu","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"2026012110531349100_CR36","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s40262-022-01139-w","article-title":"First-in-patient phase I\/II study of upacicalcet in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: pharmacokinetic and pharmacodynamic properties","volume":"61","author":"Kazama","year":"2022","journal-title":"Clin Pharmacokinet"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-024-02119-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/38\/2\/415\/66010342\/joneph_38_2_2119.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-024-02119-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/38\/2\/415\/66010342\/joneph_38_2_2119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T15:53:23Z","timestamp":1769010803000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/2\/415\/8307177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,15]]},"references-count":36,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,10,15]]},"published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-024-02119-y","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3,1]]},"published":{"date-parts":[[2024,10,15]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No ethical approval or informed consent was needed for this manuscript as it is a review article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors certify that they have no affiliations with, or involvement in, any organization or entity with any financial interest or non-financial interest in the subject matter or materials discussed in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}